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Abstract Background: This study was designed to demonstrate the non-inferiority (NI) in
overall survival (OS) of suspension of androgen deprivation therapy (ADT) versus mainte-
nance and intermittent versus continuous docetaxel administration in metastatic castration-
resistant prostate cancer (mCRPC) patients.
Patients and methods: mCRPC patients were randomised to first-line docetaxel with mainte-
nance or suspension of ADT. Patients attaining a prostate-specific antigen (PSA) response af-
ter four chemotherapy cycles underwent second randomisation to receive continuous or
intermittent docetaxel therapy. Six hundred patients were to be randomised to achieve 80%
statistical power to demonstrate an NI hazard ratio (HR) of 1.25 of interruption versus main-
tenance of ADT.
Results: The trial was prematurely closed when 198 participants were randomised. OS was
similar in patients who continued (NZ 96) versus those who interrupted (nZ 102) ADT dur-
ing docetaxel therapy (HR 0.98, 95% confidence interval [CI] 0.72e1.33] and those on a
continuous (N Z 35) versus an intermittent (N Z 42) docetaxel schedule (HR 0.86, 95%
CI 0.55e1.43). No difference in radiological progression-free survival, PSA response, or
toxicity was observed between the study arms. The actual NI hazard margins of OS in Arms
A and B patients were 1.33 and 1.43, respectively.
Conclusions: This trial enrolled one-third of the planned patients; this main weakness dramat-
ically limits the interpretation of the results. ADT discontinuation and switching to an inter-
mittent schedule did not seem to affect docetaxel efficacy. The absence of testosterone recovery
in the majority of patients could have been a contributory factor. In men with mCRPC, ADT
discontinuation should only be done with regular biochemical and clinical monitoring, with
the option of quickly restarting ADT at disease progression.
ª 2021 Elsevier Ltd. All rights reserved.
1. Introduction
Docetaxel improves survival in men with metastatic
castration-resistant prostate cancer (mCRPC) and is a
standard therapy in this setting. Previous androgen
deprivation therapy (ADT) was maintained during
docetaxel in two pivotal trials [1,2], as recommended by
current international guidelines [3]. One [4] of five
retrospective studies [4e8] on the efficacy of ADT
maintenance during chemotherapy in castration-resis-
tant prostate cancer patients showed a survival advan-
tage of the combination treatment. Up to ten docetaxel
cycles are recommended in the management of mCRPC
patients; however, long-term administration is associ-
ated with adverse effects and a negative impact on
quality of life (QoL) [9].
An intermittent schedule has the advantage that
prolonged exposure is minimised and long-term are
toxicities prevented [10,11]. Here, we report the findings
of a multicenter, prospective randomised clinical trial
conducted by the Piemonte Oncology Network to test in
mCRPC patients the non-inferiority (NI) of interruption
versus maintenance of ADT during docetaxel adminis-
tration and the intermittent versus the continuous
docetaxel schedule.
2. Patients and methods
2.1. Study design and participants
This randomised Phase 3 study involved 19 Italian
oncology centres (see Appendix 1) (NCT01224405,
Eudract 2010-019004-24). The main inclusion criteria
were histologically confirmed prostate adenocarcinoma,
a metastatic disease that had progressed to ADT despite
castrate serum testosterone levels ("50 ng/dL); Eastern
Cooperative Oncology Group performance status "2;
and adequate hepatic, renal, and bone marrow function.
The main exclusion criteria were elevated prostate-
specific antigen (PSA) without radiological progres-
sion, prior cytotoxic chemotherapy, history of other
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cancers, brain metastases, peripheral neuropathy, and
other serious medical conditions.
The trial was approved by the ethics committee of
each study site. A written, informed consent was ob-
tained from all patients.
2.2. Randomization and treatment
Patients were randomly assigned in permuted blocks
(sizes 4, 8, and 12) to receive docetaxel for four cycles
with maintenance (Arm A) or suspension (Arm B) of
ADT. The randomization sequence was stratified by
each study centre where the patients were enrolled. The
patients initially received four cycles of intravenous
docetaxel (75 mg/m2 on Day 1 every 21 days) together
with oral prednisone (5 mg BID).
ADT was stopped till disease progression in Arm B
patients and then resumed. Patients with radiological
progression after Cycle 4 were withdrawn from the
study and followed up till death. In patients without
radiological progression and increased, stable, or a
<50% decrease in PSA from baseline, docetaxel was
continued till radiological or clinical progression, un-
acceptable toxicity, or for a maximum of ten cycles.
Patients attaining a PSA response after four cycles
(>50% reduction from baseline) underwent second
randomisation to continue docetaxel till progression or
completion of ten cycles (Arm AB1) or interrupt doce-
taxel until PSA rose by 50% (at least 10 ng/mL) or
disease progression (Arm AB2), at which time treatment
was resumed (Fig. 1).
Physical examination and baseline blood tests were
repeated at 3-week intervals during docetaxel therapy.
Serum PSA and serum testosterone levels were
measured at baseline, after four docetaxel cycles, and
every 3 months thereafter till disease progression. Im-
aging studies (computed tomography and bone scans)
were performed at baseline, every 6 months, as well as to
document radiological progression if PSA increased by
>25%, bone pain worsened, or physical condition
deteriorated. Bone pain and QoL were assessed via the
McGill pain questionnaire and the Functional Assess-
ment of Cancer Therapy-Prostate (FACT-P) question-
naire, respectively [12,13], at baseline, at the end of
Cycle 4, and every 6 months thereafter.
2.3. Outcomes
The primary efficacy outcome was overall survival (OS),
defined as the interval from randomisation to death
from any cause or to the date at which the patient was
last known to be alive. The secondary outcomes
were time to biochemical progression after first and
second randomisation, measured as the interval from
randomisation to the earliest event of PSA progression,
clinical progression, death from any cause, or the last
known date of follow-up without PSA progression; time
to metastatic progression from the first and second
randomisation, defined as time to the earliest sign of
radiographic progression; PSA response, defined as a
reduction of >50% over baseline in two or more PSA
measurements obtained at least 4 weeks apart; frequency
of severe toxicity at each course of chemotherapy and
every 3 months during follow-up according to the Na-
tional Cancer Institute Common Terminology Criteria
for Adverse Events (version 3) [14]; QoL assessment
(FACT-P questionnaire at baseline, at the end of Cycle 4
of chemotherapy, and every 6 months thereafter).
2.4. Statistical analysis
The main objective of the study was to demonstrate the
NI in the survival of ADT suspension versus mainte-
nance (Arm A versus Arm B) and to demonstrate the NI
in the survival of intermittent versus continuous doce-
taxel (Arm AB1 versus AB2). The sample size was
calculated in relation to the comparison between Arm A
and Arm B and based on an alpha error (one sided) of
0.05, beta error of 0.20, hazard ratio (HR)of 1.25, below
which the experimental group can be considered not
inferior to the standard group, expected OS of 30% at 2
years, 4-year enrolment period, minimum follow-up of 2
years, and interim analysis (according to O’Brien and
Fleming) planned at the end of year 3.
Based on these assumptions, 566 patients had to be
enrolled, and at least 460 events (using a log-rank test)
recorded to demonstrate NI between arms A and B with
the predefined delta. Furthermore, assuming that 5% ofFig. 1. Consort diagram.
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patients would be unavailable for the main analysis
because of loss to follow-up or violation of study eligibility
criteria, the planned enrolment was a total of 600 patients.
At the end of the first four docetaxel cycles, approxi-
mately 55% of patients were expected not to have attained
a reduction of at least 50% in basal PSA or to have expe-
rienced disease progression; accordingly, 270 patients
would have undergone second randomisation. This esti-
mated sample size for the second comparison would have
yielded a statistical power of at least 73%, with aminimum
follow-up of 36 months from the second randomisation,
an NI limit (HR 1.33, one-tailed alpha error 0.05). A
comparison between Arm AB1 and Arm AB2 was plan-
ned when approximately 250 total deaths had occurred in
the group eligible for second randomisation.
All randomised patients were included in the analysis
according to the intention-to-treat principle, as were
treated subjects per protocol. OS and disease-free survival
were evaluated with the KaplaneMeier method and
compared with the log-rank test. The Coxmodel was used
to estimate the HRs and confidence intervals (95%)
adjusted for the main prognostic factors. The proportion
of toxicity and responses in the two arms was compared
using the chi-squared orFisher’s exact test, as appropriate.
In an ancillary study,we explored the prognostic role of
serum testosterone levels in Arm B patients. To reduce the
inherent bias of patients with early progression and death,
and as no increase in testosterone was expected in the first
weeks after stopping ADT, survival analyses were per-
formed at Month 3 as a fixed landmark point. Patients
who experienced disease progression or death before the
landmark point were excluded from the analysis.
3. Results
3.1. Patient characteristics
Of a total of 199 eligible patients, 198 were randomly
allocated to receive either docetaxel 75 mg/m2 every 3
weeks with the maintenance of ADT (Arm A, n Z 96)
Table 1
Patient characteristics.
Patients characteristics Arm A (ADT suspension,
N Z 96), n (%)
Arm B (ADT maintenance,
N Z 102), n (%)
P
Median age (range) 64.86 (47e78) 65.19 (50e79) 0.87
Stage at diagnosis
Stage I 1 (1) 0 0.67
Stage II 19 (19.8) 18 (17.6)
Stage III 24 (25) 30 (29.4)
Stage IV 52 (54.2) 54 (52.9)
Gleason score
<7 9 (9.4) 11 (10.8) 0.24
7 34 (35.4) 25 (24.5)
>7 53 (52.2) 66 (64.7)
PSA at diagnosis, median (range) 19 (0e2531) 21.8 (0e1072) 0.66
PSA at randomisation, median (range) 57.35 (1.23e2995) 48.9 (4.9e1146) 0.91
Treatment at diagnosis
Radical prostatectomy 44 (45.8) 39 (38.2) 0.32
Radiation therapy 19 (19.9) 19 (18.6)
Androgen deprivation therapy 32 (33.3) 39 (38.2)
Observation 1 (1) 5 (4.9)
Time from metastatic disease to
first randomisation (months), median (range)
10.32 (0e122) 10.27 (0e193) 0.94
Disease-free survival (months), median (range) 35.82 (5e184.23) 33.88 (4.23e208.6) 0.99
Disease sites at inclusion in the trial
Prostate 9 (9.4) 17 (16.7) 0.11
Bone 65 (67.7) 91 (89.2)
Lymph nodes 49 (51) 38 (37.3)
Soft tissue 2 (2.1) 5 (4.9)
Visceral 17 (17.7) 15 (14.7)
No of metastatic sites
1 58 (60.4) 55 (53.9) 0.27
2 28 (29.2) 32 (31.4)
>2 10 (10.4) 15 (14.7)
ECOG PS at randomization
0 66 (68.8) 78 (76.5) 0.22
1 30 (31.3) 24 (23.5)
>1 0 0
Median BMI (range) 27.04 (17e38) 27.47 (3e53) 0.97
Median testosterone levels at
randomisation (range)
0.11 (0-0.5) 0.10 (0-0.5) 0.90
BMI, body mass index.
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or docetaxel 75 mg/m2 every 3 weeks with ADT sus-
pension (Arm B, n Z 102; Fig. 1). Baseline patient and
tumour characteristics were similar for both groups
(Table 1). One-half of the patients in both groups had
Stage IV disease at diagnosis. Bone was the most
frequent site of metastases: 65 (68%) Arm A and 91
(89%) Arm B patients, respectively.
3.2. Efficacy
The median duration of follow-up was 88.5 months:
PSA has increased preceding radiological progression in
185 (93%) patients, radiological progression occurred in
188 (95%), and 165 (83%) died. The median OS was 23.3
months in Arm A and 24.8 months in Arm B patients
(HR 0.98, 95% CI 0.72e1.33; Fig. 2a). The actual NI
margin of OS was an HR of 1.33. The median
biochemical progression-free survival (bPFS) was 8.0
months and 6.2 months (HR 1.13, 95% CI 0.85e1.51;
Fig. 2b), and the median clinical/radiological progres-
sion-free survival (c/rPFS) was 10.3 months and 10.8
months (HR 0.98, 95% CI 0.73e1.31; Fig. 2c) in Arm A
and Arm B patients, respectively. After four cycles of
docetaxel, PSA was reduced >50% in 42 (43.8%) Arm A
and 39 (38.2%) Arm B patients; PSA was reduced <50%
in 31 (32.2%) and 35 (34.3%) and increased in 23 (24%)
and 28 (27.5%) Arm A and Arm B patients, respectively.
3.3. Toxicity
The most frequent adverse events were gastrointestinal
(nausea, vomiting, and diarrhoea), fatigue, and neu-
tropenia. Adverse event frequency and severity were
similar in the two groups (Table 2).
3.4. Serum testosterone levels and disease outcome
Testosterone serum levels after four docetaxel cycles
were above the castration threshold (0.5 mg/dl) in 19
(18%) Arm B patients and within the normal range in
only two patients. We evaluated the prognostic effect of
serum testosterone above the castration range. Four
patients relapsed or died within the first 3 months
(landmark point), so the analysis was performed in 98
assessable patients. The median OS was 24.8 months in
the castrated (T#) and 27.5 months in the patients with
testosterone levels above the castration range (T!; HR
0.75, 95% CI 0.46e1.3; Fig. 3). The median c/rPFS was
11.5 months in the T! and 10.4 months in the T# pa-
tients (HR 1.04, 95% CI 0.61e1.77); the median
bPFS was 8.2 and 6.2 months, respectively (HR 0.75,
95% CI 0.44e1.30), data not shown. Serum testosterone
levels at subsequent time points were unavailable in
most patients and were not analysed.
Fig. 2. (A) KaplaneMeier curves of overall survival of Arm A and
Arm B patients. (B) KaplaneMeier curves of biochemical
progression-free survival of Arm A and Arm B patients. (C)
KaplaneMeier curves of clinical progression-free survival of Arm
A and Arm B patients.
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3.5. Intermittent versus continuous docetaxel
administration
Four of the 81 patients eligible for the second random-
isation refused to participate in this second study and
continued with docetaxel till progression or ten cycles.
Among the remaining 77 patients, 35 were randomised
to continuous (Arm AB1) and 42 to intermittent doce-
taxel (Arm AB2). OS was 28.7 and 31.8 months in the
Arm AB1 and the Arm AB2 patients, respectively (HR
0.86, 95% CI 0.55e1.43; Fig. 4), whereas c/rPFS was
8.27 and 9.2 months in the two arms, respectively (HR
1.13, 95% CI 0.72e1.79). The median bPFS was longer
in the AB2 patients (intermittent schedule) than in the
AB1 patients (continuous schedule): 6.1 versus 2.7
months (HR 2.6, 95% CI 1.6e4.2; Figs. S1eS2, Sup-
plementary Material).
3.6. Quality of life
Patients completed the FACT-P questionnaire at base-
line, at the end of four cycles of chemotherapy, and at 6
months after randomisation: 101 at baseline and Cycle 4
(first randomisation) and 67 at 6 months. Only 30 of the
77 (39%) completed the questionnaire at second ran-
domisation. No statistically significant changes in QoL
for the two groups were noted (Fig. 5).
4. Discussion
Our findings suggest a similar survival perspective for
the patients who interrupted ADT during docetaxel
therapy and those who maintained it. We observed no
significant difference in the secondary end-points be-
tween the two treatment arms: radiological progression-
free survival, bPFS, and PSA response. Although these
data are original and of potential interest, our study has
several limitations. First, the accrual was less than that
needed to achieve sufficient power to adequately address
the NI in OS between the two arms. Therefore, the
Table 2
Toxicity.
Toxicity grade Arm A (N Z 96),
n (%)




0 58 (60.4) 61 (60.4) 0.93
1e2 30 (31.3) 40 (39.2)
3e4 8 (8.3) 1 (1)
Neurological
0 67 (69.8) 77 (75.5) 0.37
1e2 29 (30.2) 24 (23.5)
3e4 0 (0) 1 (1)
Neutropenia
0 71 (74) 69 (67.7) 0.56
1e2 9 (9.3) 10 (9.8)
3e4 16 (16.7) 23 (22.5)
Anaemia
0 70 (72.9) 71 (69.6) 0.86
1e2 24 (25) 29 (28.4)
3e4 2 (2.1) 2 (2)
Thrombocytopenia
0 88 (91.7) 94 (92.2) 0.81
1e2 6 (6.3) 7 (6.9)
3e4 2 (2.1) 1 (1)
Fatigue
0 59 (61.5) 53 (52) 0.15
1-2 33 (34.4) 38 (37.3)
3-4 4 (4.2) 11 (10.8)
Alopecia
0 78 (81.3) 80 (78.4) 0.65
1e2 12 (12.5) 12 (11.8)
3e4 6 (6.3) 10 (9.8)
Nail changes
0 81 (84.4) 88 (86.3) 0.57
1e2 14 (14.6) 14 (13.7)
3e4 1 (1) 0 (0)
Fig. 3. KaplaneMeier curves of overall survival in patients
attaining testosterone levels above the castration levels (T!)
compared with those who did not (T#). A landmark at 3 months
was introduced.
Fig. 4. KaplaneMeier curves of overall survival of patients sub-
mitted to continuous (Arm AB1) or intermittent (Arm AB2)
docetaxel schedule administration after PSA response at four
cycles.
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preplanned NI hazard margin of 1.25 increased to 1.33,
considering the actual accrual of the study. Second, the
comparison between the intermittent and the continuous
docetaxel schedule was clearly underpowered: the NI
hazard margin was 1.43.
Furthermore, our assumption was that suspension of
ADT would have resulted in an increase in testosterone
levels in a consistent number of patients and that this
increase would not have been detrimental. Unfortu-
nately, only 7% of patients randomised to the ADT
withdrawal arm achieved a serum testosterone level
>0.5 ng/ml after 3 months. This contrasts with inter-
mittent androgen withdrawal studies that demonstrated
that the time to increase in testosterone above the
castration threshold is about 3 months in the off-therapy
phase [15,16]. The long-term ADT exposure may have
induced testicular atrophy in the majority of our pa-
tients, which prevented the restoration of testosterone
synthesis after ADT suspension. A previous study re-
ported that most patients who had received long-term
ADT therapy (>4 years) remained castrated for up to
2.5 years after therapy cessation [17]. These data
notwithstanding, the outcome was not worse in the pa-
tients attaining serum testosterone >0.5 ng/ml at 3
months; the median survival was 4 months longer than
for their counterparts with levels within the castration
range, although this difference was not statistically
significant.
A previous study found a direct relationship between
serum testosterone levels and OS in mCRPC patients
receiving docetaxel [18]. The prognostic role of testos-
terone levels in mCRPC was documented in a trial-
based meta-analysis that included patients treated with
new generation hormone therapies [19]. A plausible
explanation for this apparent testosterone paradox is
that higher testosterone levels during docetaxel therapy
may maintain prostate cancer cells in a prolonged
hormone-sensitive state, thus enhancing the efficacy of
subsequent hormone therapies [20].
In our study, two Arm B patients obtained a signifi-
cant clinical benefit after ADT resumption at disease
progression to docetaxel [21]. No difference in docetaxel
toxicity was observed between the two study arms, and
no differences in overall score or single QoL items were
observed in the subgroup in which QoL was assessed. A
previous study demonstrated that docetaxel clearance is
consistently increased in castrated men with potentially
better tolerability but a reduction in drug efficacy. The
failure to recover castration status by most of the Arm B
patients could account at least in part for the lack of
difference in efficacy and toxicity of docetaxel therapy
between the two arms [22].
With regard to the intermittent docetaxel arm, nine
single-arm Phase II studies [10] and one randomised
clinical trial [11], the PRINCE study, differed in design
and docetaxel schedule from our study in which we
applied the criterion of a reduction of at least 50% in
PSA to enter the study.
Our results suggest no difference in OS, progression-
free survival (PFS), PSA response, and toxicity between
the treatment arms, as reported by the PRINCE trial.
But, again, our trial was dramatically underpowered. As
observed in the PRINCE study, biochemical PFS was
significantly longer in the intermittent arm, but this
observation is of limited clinical impact [23].
There were no differences in QoL between the pa-
tients who maintained and those who temporarily sus-
pended ADT. The short follow-up for QoL and the
small number of patients whose testosterone rose above
the castration threshold may explain these results.
In conclusion, in this trial, discontinuation of ADT
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PROSTATE SPECIFIC SCALE Arm B
Fig. 5. Changes in quality of life at baseline and at 3 and 6 months after first randomization.
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to change docetaxel efficacy, mainly because no
biochemical signs of testosterone recovery were seen in
many patients. This trial enrolled one-third of the
planned patients, and this weakness dramatically limits
the interpretation of the results. Nonetheless, our find-
ings suggest that if ADT is discontinued, testosterone/
PSA levels should be regularly monitored and patients
clinically reviewed, with the option of quickly restarting
ADT at progression.
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